UCB SA has identified imidazotriazine derivatives acting as interleukin-17 (IL-17) modulators reported to be useful for the treatment of inflammation and autoimmune diseases.
Recursion Pharmaceuticals Inc. has synthesized molecular glue degraders acting as RBM39 degradation inducers reported to be useful for the treatment of renal cell carcinoma.
Immvention Therapeutix Inc. has disclosed benzimidazole-containing compounds acting as inflammasome inhibitors reported to be useful for the treatment of inflammatory disorders.
Caregen Co. Ltd. has described peptides reported to be useful for the treatment of cartilage injury, fracture, intervertebral disc herniation, degenerative intervertebral disc disorder, osteoarthritis, osteomalacia and muscular injury.
Researchers at Risen (Shanghai) Pharma Eng Co. Ltd. and Risen (Suzhou) Pharma Tech Co. Ltd. have divulged GTPase KRAS inhibitors reported to be useful for the treatment of cancer.
Scientists at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of cardiovascular disorders.
Sanofi SA has synthesized interleukin-17A (IL-17A)/interleukin-17 receptor A (IL-17RA) interaction inhibitors reported to be useful for the treatment of psoriasis, rheumatoid arthritis, radiographic axial spondyloarthritis (ankylosing spondylitis), multiple sclerosis, asthma, chronic obstructive pulmonary disease, atopic dermatitis and systemic lupus erythematosus, among others.
Praxis Precision Medicines Inc. has disclosed inhibitors of potassium channel subfamily T member 1 (KCNT1) and its mutants reported to be useful for the treatment of Brugada syndrome, heart failure, muscle disorders, myocardial infarction, neurological disorders, pain, pruritus and psychiatric disorders.
NMD Pharma ApS has described chloride channel protein 1 (CLCN1; ClC-1) channel blockers reported to be useful for the treatment of myasthenia gravis, Lambert-Eaton syndrome, critical illness myopathy, amyotrophic lateral sclerosis, spinal muscular atrophy, Guillain-Barré syndrome, post-poliomyelitic and chronic fatigue syndrome, among others.
SRI International has divulged lipoxygenase inhibitors, particularly polyunsaturated fatty acid 5-lipoxygenase (ALOX5) and/or ALOX15, reported to be useful for the treatment of bacterial infections.
RSS
